Mepolizumabe na doença respiratória exacerbada por aspirina - DREA
Mepolizumab in aspirin-exacerbated respiratory disease - AERD
Mariele Morandin Lopes; Claudia Leiko Yonekura Anagusko; Fábio Fernandes Morato Castro
Resumo
Relato de caso que ilustra a eficácia e a segurança do uso do mepolizumabe na doença respiratória exacerbada por aspirina (DREA). A utilização de anticorpo monoclonal no tratamento desta doença respiratória de difícil tratamento tem possibilitado o controle da inflamação crônica e o maior conhecimento sobre a fisiopatogenia da doença.
Palavras-chave
Abstract
This case report shows the efficacy and safety of mepolizumab in aspirin-exacerbated respiratory disease (AERD). The use of monoclonal antibodies in the treatment of this severe disease has provided improved control of chronic inflammation and greater understanding about the pathophysiology of the disease.
Keywords
Referências
1. Samter M, Beers RF Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68:975‑83.
2. Dias GMFS, Assis JP, Andrade MC, Aun MV, Kalil J, Giavina-Bianchi P, et al. Diagnóstico e tratamento da DREA: realidades da prática clínica. Braz J Allergy Immunol. 2018;2(1):123-9.
3. Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407-13.
4. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135:676-81.
5. Scott DR, White AA. Approach to desensitization in aspirinexacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;112:13-7.
6. Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease - New Prime Suspects. N Engl J Med. 2016;374:484-8.
7. Szczeklik A, Sladeck K, Dworski R, Nizankowska E, Soja J, Sheller J, Oates J. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1608-14.
8. White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease. N Engl J Med. 2018 Sep 13;379(11):1060-70.
9. Woessner, KM. Update on Aspirin-Exacerbated Respiratory Disease. Curr Allergy Asthma Rep. 2017;17:2.
10. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172-4.
11. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): A dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245-52.
12. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald M, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371:1198-207.
13. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8.
14. Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KN. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018;6(3):1045‑47.
Submetido em:
29/05/2019
Aceito em:
11/06/2019
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email